カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の抗毒素免疫グロブリン市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Antivenom Immunoglobulin Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19156）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19156
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：107
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の抗毒素免疫グロブリン市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

抗毒素免疫グロブリン市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の抗毒素免疫グロブリンの市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

抗毒素免疫グロブリン市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・多価抗毒素、一価抗毒素

用途別セグメントは次のように区分されます。
・非営利団体、病院、診療所

世界の抗毒素免疫グロブリン市場の主要な市場プレーヤーは以下のとおりです。
・CSL、Merck、BTG、Pfizer、Haffkine Bio-Pharmaceutical、Rare Disease Therapeutics、Flynn Pharma、Vins Bioproducts、Bharat Serums and Vaccines、Serum Biotech、MicroPharm

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、抗毒素免疫グロブリン製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な抗毒素免疫グロブリンメーカーの企業概要、2019年～2022年までの抗毒素免疫グロブリンの価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な抗毒素免疫グロブリンメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別抗毒素免疫グロブリンの販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの抗毒素免疫グロブリンの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での抗毒素免疫グロブリン市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および抗毒素免疫グロブリンの産業チェーンを掲載しています。
・第13、14、15章では、抗毒素免疫グロブリンの販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- 抗毒素免疫グロブリンの概要
- 種類別分析（2017年vs2021年vs2028年）：多価抗毒素、一価抗毒素
- 用途別分析（2017年vs2021年vs2028年）：非営利団体、病院、診療所
- 世界の抗毒素免疫グロブリン市場規模・予測
- 世界の抗毒素免疫グロブリン生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- CSL、Merck、BTG、Pfizer、Haffkine Bio-Pharmaceutical、Rare Disease Therapeutics、Flynn Pharma、Vins Bioproducts、Bharat Serums and Vaccines、Serum Biotech、MicroPharm
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：多価抗毒素、一価抗毒素
・用途別分析2017年-2028年：非営利団体、病院、診療所
・抗毒素免疫グロブリンの北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・抗毒素免疫グロブリンのヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・抗毒素免疫グロブリンのアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・抗毒素免疫グロブリンの南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・抗毒素免疫グロブリンの中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Antivenom Immunoglobulin market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Antivenom Immunoglobulin market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Non-profit Institutions accounting for % of the Antivenom Immunoglobulin global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Polyvalent Antivenom segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Antivenom Immunoglobulin include CSL, Merck, BTG, Pfizer, and Haffkine Bio-Pharmaceutical, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Antivenom Immunoglobulin market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Polyvalent Antivenom
Monovalent Antivenom
Market segment by Application can be divided into
Non-profit Institutions
Hospitals and Clinics
The key market players for global Antivenom Immunoglobulin market are listed below:
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Antivenom Immunoglobulin product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Antivenom Immunoglobulin, with price, sales, revenue and global market share of Antivenom Immunoglobulin from 2019 to 2022.
Chapter 3, the Antivenom Immunoglobulin competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Antivenom Immunoglobulin breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Antivenom Immunoglobulin market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Antivenom Immunoglobulin.
Chapter 13, 14, and 15, to describe Antivenom Immunoglobulin sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Antivenom Immunoglobulin Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Antivenom Immunoglobulin Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Polyvalent Antivenom
1.2.3 Monovalent Antivenom
1.3 Market Analysis by Application
1.3.1 Overview: Global Antivenom Immunoglobulin Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Non-profit Institutions
1.3.3 Hospitals and Clinics
1.4 Global Antivenom Immunoglobulin Market Size & Forecast
1.4.1 Global Antivenom Immunoglobulin Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Antivenom Immunoglobulin Sales in Volume (2017-2028)
1.4.3 Global Antivenom Immunoglobulin Price (2017-2028)
1.5 Global Antivenom Immunoglobulin Production Capacity Analysis
1.5.1 Global Antivenom Immunoglobulin Total Production Capacity (2017-2028)
1.5.2 Global Antivenom Immunoglobulin Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Antivenom Immunoglobulin Market Drivers
1.6.2 Antivenom Immunoglobulin Market Restraints
1.6.3 Antivenom Immunoglobulin Trends Analysis
2 Manufacturers Profiles
2.1 CSL
2.1.1 CSL Details
2.1.2 CSL Major Business
2.1.3 CSL Antivenom Immunoglobulin Product and Services
2.1.4 CSL Antivenom Immunoglobulin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Merck
2.2.1 Merck Details
2.2.2 Merck Major Business
2.2.3 Merck Antivenom Immunoglobulin Product and Services
2.2.4 Merck Antivenom Immunoglobulin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 BTG
2.3.1 BTG Details
2.3.2 BTG Major Business
2.3.3 BTG Antivenom Immunoglobulin Product and Services
2.3.4 BTG Antivenom Immunoglobulin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Antivenom Immunoglobulin Product and Services
2.4.4 Pfizer Antivenom Immunoglobulin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Haffkine Bio-Pharmaceutical
2.5.1 Haffkine Bio-Pharmaceutical Details
2.5.2 Haffkine Bio-Pharmaceutical Major Business
2.5.3 Haffkine Bio-Pharmaceutical Antivenom Immunoglobulin Product and Services
2.5.4 Haffkine Bio-Pharmaceutical Antivenom Immunoglobulin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Rare Disease Therapeutics
2.6.1 Rare Disease Therapeutics Details
2.6.2 Rare Disease Therapeutics Major Business
2.6.3 Rare Disease Therapeutics Antivenom Immunoglobulin Product and Services
2.6.4 Rare Disease Therapeutics Antivenom Immunoglobulin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Flynn Pharma
2.7.1 Flynn Pharma Details
2.7.2 Flynn Pharma Major Business
2.7.3 Flynn Pharma Antivenom Immunoglobulin Product and Services
2.7.4 Flynn Pharma Antivenom Immunoglobulin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Vins Bioproducts
2.8.1 Vins Bioproducts Details
2.8.2 Vins Bioproducts Major Business
2.8.3 Vins Bioproducts Antivenom Immunoglobulin Product and Services
2.8.4 Vins Bioproducts Antivenom Immunoglobulin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Bharat Serums and Vaccines
2.9.1 Bharat Serums and Vaccines Details
2.9.2 Bharat Serums and Vaccines Major Business
2.9.3 Bharat Serums and Vaccines Antivenom Immunoglobulin Product and Services
2.9.4 Bharat Serums and Vaccines Antivenom Immunoglobulin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Serum Biotech
2.10.1 Serum Biotech Details
2.10.2 Serum Biotech Major Business
2.10.3 Serum Biotech Antivenom Immunoglobulin Product and Services
2.10.4 Serum Biotech Antivenom Immunoglobulin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 MicroPharm
2.11.1 MicroPharm Details
2.11.2 MicroPharm Major Business
2.11.3 MicroPharm Antivenom Immunoglobulin Product and Services
2.11.4 MicroPharm Antivenom Immunoglobulin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Antivenom Immunoglobulin Breakdown Data by Manufacturer
3.1 Global Antivenom Immunoglobulin Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Antivenom Immunoglobulin Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Antivenom Immunoglobulin
3.4 Market Concentration Rate
3.4.1 Top 3 Antivenom Immunoglobulin Manufacturer Market Share in 2021
3.4.2 Top 6 Antivenom Immunoglobulin Manufacturer Market Share in 2021
3.5 Global Antivenom Immunoglobulin Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Antivenom Immunoglobulin Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Antivenom Immunoglobulin Market Size by Region
4.1.1 Global Antivenom Immunoglobulin Sales in Volume by Region (2017-2028)
4.1.2 Global Antivenom Immunoglobulin Revenue by Region (2017-2028)
4.2 North America Antivenom Immunoglobulin Revenue (2017-2028)
4.3 Europe Antivenom Immunoglobulin Revenue (2017-2028)
4.4 Asia-Pacific Antivenom Immunoglobulin Revenue (2017-2028)
4.5 South America Antivenom Immunoglobulin Revenue (2017-2028)
4.6 Middle East and Africa Antivenom Immunoglobulin Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Antivenom Immunoglobulin Sales in Volume by Type (2017-2028)
5.2 Global Antivenom Immunoglobulin Revenue by Type (2017-2028)
5.3 Global Antivenom Immunoglobulin Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Antivenom Immunoglobulin Sales in Volume by Application (2017-2028)
6.2 Global Antivenom Immunoglobulin Revenue by Application (2017-2028)
6.3 Global Antivenom Immunoglobulin Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Antivenom Immunoglobulin Sales by Type (2017-2028)
7.2 North America Antivenom Immunoglobulin Sales by Application (2017-2028)
7.3 North America Antivenom Immunoglobulin Market Size by Country
7.3.1 North America Antivenom Immunoglobulin Sales in Volume by Country (2017-2028)
7.3.2 North America Antivenom Immunoglobulin Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Antivenom Immunoglobulin Sales by Type (2017-2028)
8.2 Europe Antivenom Immunoglobulin Sales by Application (2017-2028)
8.3 Europe Antivenom Immunoglobulin Market Size by Country
8.3.1 Europe Antivenom Immunoglobulin Sales in Volume by Country (2017-2028)
8.3.2 Europe Antivenom Immunoglobulin Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Antivenom Immunoglobulin Sales by Type (2017-2028)
9.2 Asia-Pacific Antivenom Immunoglobulin Sales by Application (2017-2028)
9.3 Asia-Pacific Antivenom Immunoglobulin Market Size by Region
9.3.1 Asia-Pacific Antivenom Immunoglobulin Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Antivenom Immunoglobulin Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Antivenom Immunoglobulin Sales by Type (2017-2028)
10.2 South America Antivenom Immunoglobulin Sales by Application (2017-2028)
10.3 South America Antivenom Immunoglobulin Market Size by Country
10.3.1 South America Antivenom Immunoglobulin Sales in Volume by Country (2017-2028)
10.3.2 South America Antivenom Immunoglobulin Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Antivenom Immunoglobulin Sales by Type (2017-2028)
11.2 Middle East & Africa Antivenom Immunoglobulin Sales by Application (2017-2028)
11.3 Middle East & Africa Antivenom Immunoglobulin Market Size by Country
11.3.1 Middle East & Africa Antivenom Immunoglobulin Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Antivenom Immunoglobulin Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Antivenom Immunoglobulin and Key Manufacturers
12.2 Manufacturing Costs Percentage of Antivenom Immunoglobulin
12.3 Antivenom Immunoglobulin Production Process
12.4 Antivenom Immunoglobulin Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Antivenom Immunoglobulin Typical Distributors
13.3 Antivenom Immunoglobulin Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Antivenom Immunoglobulin Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Antivenom Immunoglobulin Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. CSL Basic Information, Manufacturing Base and Competitors
Table 4. CSL Major Business
Table 5. CSL Antivenom Immunoglobulin Product and Services
Table 6. CSL Antivenom Immunoglobulin Sales (K Vials), Price (USD/Vial), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Merck Basic Information, Manufacturing Base and Competitors
Table 8. Merck Major Business
Table 9. Merck Antivenom Immunoglobulin Product and Services
Table 10. Merck Antivenom Immunoglobulin Sales (K Vials), Price (USD/Vial), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. BTG Basic Information, Manufacturing Base and Competitors
Table 12. BTG Major Business
Table 13. BTG Antivenom Immunoglobulin Product and Services
Table 14. BTG Antivenom Immunoglobulin Sales (K Vials), Price (USD/Vial), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Pfizer Basic Information, Manufacturing Base and Competitors
Table 16. Pfizer Major Business
Table 17. Pfizer Antivenom Immunoglobulin Product and Services
Table 18. Pfizer Antivenom Immunoglobulin Sales (K Vials), Price (USD/Vial), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Haffkine Bio-Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 20. Haffkine Bio-Pharmaceutical Major Business
Table 21. Haffkine Bio-Pharmaceutical Antivenom Immunoglobulin Product and Services
Table 22. Haffkine Bio-Pharmaceutical Antivenom Immunoglobulin Sales (K Vials), Price (USD/Vial), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Rare Disease Therapeutics Basic Information, Manufacturing Base and Competitors
Table 24. Rare Disease Therapeutics Major Business
Table 25. Rare Disease Therapeutics Antivenom Immunoglobulin Product and Services
Table 26. Rare Disease Therapeutics Antivenom Immunoglobulin Sales (K Vials), Price (USD/Vial), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Flynn Pharma Basic Information, Manufacturing Base and Competitors
Table 28. Flynn Pharma Major Business
Table 29. Flynn Pharma Antivenom Immunoglobulin Product and Services
Table 30. Flynn Pharma Antivenom Immunoglobulin Sales (K Vials), Price (USD/Vial), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Vins Bioproducts Basic Information, Manufacturing Base and Competitors
Table 32. Vins Bioproducts Major Business
Table 33. Vins Bioproducts Antivenom Immunoglobulin Product and Services
Table 34. Vins Bioproducts Antivenom Immunoglobulin Sales (K Vials), Price (USD/Vial), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Bharat Serums and Vaccines Basic Information, Manufacturing Base and Competitors
Table 36. Bharat Serums and Vaccines Major Business
Table 37. Bharat Serums and Vaccines Antivenom Immunoglobulin Product and Services
Table 38. Bharat Serums and Vaccines Antivenom Immunoglobulin Sales (K Vials), Price (USD/Vial), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Serum Biotech Basic Information, Manufacturing Base and Competitors
Table 40. Serum Biotech Major Business
Table 41. Serum Biotech Antivenom Immunoglobulin Product and Services
Table 42. Serum Biotech Antivenom Immunoglobulin Sales (K Vials), Price (USD/Vial), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. MicroPharm Basic Information, Manufacturing Base and Competitors
Table 44. MicroPharm Major Business
Table 45. MicroPharm Antivenom Immunoglobulin Product and Services
Table 46. MicroPharm Antivenom Immunoglobulin Sales (K Vials), Price (USD/Vial), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Global Antivenom Immunoglobulin Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Vials)
Table 48. Global Antivenom Immunoglobulin Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 49. Market Position of Manufacturers in Antivenom Immunoglobulin, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 50. Global Antivenom Immunoglobulin Production Capacity by Company, (K Vials): 2020 VS 2021
Table 51. Head Office and Antivenom Immunoglobulin Production Site of Key Manufacturer
Table 52. Antivenom Immunoglobulin New Entrant and Capacity Expansion Plans
Table 53. Antivenom Immunoglobulin Mergers & Acquisitions in the Past Five Years
Table 54. Global Antivenom Immunoglobulin Sales by Region (2017-2022) & (K Vials)
Table 55. Global Antivenom Immunoglobulin Sales by Region (2023-2028) & (K Vials)
Table 56. Global Antivenom Immunoglobulin Revenue by Region (2017-2022) & (USD Million)
Table 57. Global Antivenom Immunoglobulin Revenue by Region (2023-2028) & (USD Million)
Table 58. Global Antivenom Immunoglobulin Sales by Type (2017-2022) & (K Vials)
Table 59. Global Antivenom Immunoglobulin Sales by Type (2023-2028) & (K Vials)
Table 60. Global Antivenom Immunoglobulin Revenue by Type (2017-2022) & (USD Million)
Table 61. Global Antivenom Immunoglobulin Revenue by Type (2023-2028) & (USD Million)
Table 62. Global Antivenom Immunoglobulin Price by Type (2017-2022) & (USD/Vial)
Table 63. Global Antivenom Immunoglobulin Price by Type (2023-2028) & (USD/Vial)
Table 64. Global Antivenom Immunoglobulin Sales by Application (2017-2022) & (K Vials)
Table 65. Global Antivenom Immunoglobulin Sales by Application (2023-2028) & (K Vials)
Table 66. Global Antivenom Immunoglobulin Revenue by Application (2017-2022) & (USD Million)
Table 67. Global Antivenom Immunoglobulin Revenue by Application (2023-2028) & (USD Million)
Table 68. Global Antivenom Immunoglobulin Price by Application (2017-2022) & (USD/Vial)
Table 69. Global Antivenom Immunoglobulin Price by Application (2023-2028) & (USD/Vial)
Table 70. North America Antivenom Immunoglobulin Sales by Country (2017-2022) & (K Vials)
Table 71. North America Antivenom Immunoglobulin Sales by Country (2023-2028) & (K Vials)
Table 72. North America Antivenom Immunoglobulin Revenue by Country (2017-2022) & (USD Million)
Table 73. North America Antivenom Immunoglobulin Revenue by Country (2023-2028) & (USD Million)
Table 74. North America Antivenom Immunoglobulin Sales by Type (2017-2022) & (K Vials)
Table 75. North America Antivenom Immunoglobulin Sales by Type (2023-2028) & (K Vials)
Table 76. North America Antivenom Immunoglobulin Sales by Application (2017-2022) & (K Vials)
Table 77. North America Antivenom Immunoglobulin Sales by Application (2023-2028) & (K Vials)
Table 78. Europe Antivenom Immunoglobulin Sales by Country (2017-2022) & (K Vials)
Table 79. Europe Antivenom Immunoglobulin Sales by Country (2023-2028) & (K Vials)
Table 80. Europe Antivenom Immunoglobulin Revenue by Country (2017-2022) & (USD Million)
Table 81. Europe Antivenom Immunoglobulin Revenue by Country (2023-2028) & (USD Million)
Table 82. Europe Antivenom Immunoglobulin Sales by Type (2017-2022) & (K Vials)
Table 83. Europe Antivenom Immunoglobulin Sales by Type (2023-2028) & (K Vials)
Table 84. Europe Antivenom Immunoglobulin Sales by Application (2017-2022) & (K Vials)
Table 85. Europe Antivenom Immunoglobulin Sales by Application (2023-2028) & (K Vials)
Table 86. Asia-Pacific Antivenom Immunoglobulin Sales by Region (2017-2022) & (K Vials)
Table 87. Asia-Pacific Antivenom Immunoglobulin Sales by Region (2023-2028) & (K Vials)
Table 88. Asia-Pacific Antivenom Immunoglobulin Revenue by Region (2017-2022) & (USD Million)
Table 89. Asia-Pacific Antivenom Immunoglobulin Revenue by Region (2023-2028) & (USD Million)
Table 90. Asia-Pacific Antivenom Immunoglobulin Sales by Type (2017-2022) & (K Vials)
Table 91. Asia-Pacific Antivenom Immunoglobulin Sales by Type (2023-2028) & (K Vials)
Table 92. Asia-Pacific Antivenom Immunoglobulin Sales by Application (2017-2022) & (K Vials)
Table 93. Asia-Pacific Antivenom Immunoglobulin Sales by Application (2023-2028) & (K Vials)
Table 94. South America Antivenom Immunoglobulin Sales by Country (2017-2022) & (K Vials)
Table 95. South America Antivenom Immunoglobulin Sales by Country (2023-2028) & (K Vials)
Table 96. South America Antivenom Immunoglobulin Revenue by Country (2017-2022) & (USD Million)
Table 97. South America Antivenom Immunoglobulin Revenue by Country (2023-2028) & (USD Million)
Table 98. South America Antivenom Immunoglobulin Sales by Type (2017-2022) & (K Vials)
Table 99. South America Antivenom Immunoglobulin Sales by Type (2023-2028) & (K Vials)
Table 100. South America Antivenom Immunoglobulin Sales by Application (2017-2022) & (K Vials)
Table 101. South America Antivenom Immunoglobulin Sales by Application (2023-2028) & (K Vials)
Table 102. Middle East & Africa Antivenom Immunoglobulin Sales by Region (2017-2022) & (K Vials)
Table 103. Middle East & Africa Antivenom Immunoglobulin Sales by Region (2023-2028) & (K Vials)
Table 104. Middle East & Africa Antivenom Immunoglobulin Revenue by Region (2017-2022) & (USD Million)
Table 105. Middle East & Africa Antivenom Immunoglobulin Revenue by Region (2023-2028) & (USD Million)
Table 106. Middle East & Africa Antivenom Immunoglobulin Sales by Type (2017-2022) & (K Vials)
Table 107. Middle East & Africa Antivenom Immunoglobulin Sales by Type (2023-2028) & (K Vials)
Table 108. Middle East & Africa Antivenom Immunoglobulin Sales by Application (2017-2022) & (K Vials)
Table 109. Middle East & Africa Antivenom Immunoglobulin Sales by Application (2023-2028) & (K Vials)
Table 110. Antivenom Immunoglobulin Raw Material
Table 111. Key Manufacturers of Antivenom Immunoglobulin Raw Materials
Table 112. Direct Channel Pros & Cons
Table 113. Indirect Channel Pros & Cons
Table 114. Antivenom Immunoglobulin Typical Distributors
Table 115. Antivenom Immunoglobulin Typical Customers
List of Figures
Figure 1. Antivenom Immunoglobulin Picture
Figure 2. Global Antivenom Immunoglobulin Revenue Market Share by Type in 2021
Figure 3. Polyvalent Antivenom
Figure 4. Monovalent Antivenom
Figure 5. Global Antivenom Immunoglobulin Revenue Market Share by Application in 2021
Figure 6. Non-profit Institutions
Figure 7. Hospitals and Clinics
Figure 8. Global Antivenom Immunoglobulin Revenue, (USD Million) & (K Vials): 2017 & 2021 & 2028
Figure 9. Global Antivenom Immunoglobulin Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Antivenom Immunoglobulin Sales (2017-2028) & (K Vials)
Figure 11. Global Antivenom Immunoglobulin Price (2017-2028) & (USD/Vial)
Figure 12. Global Antivenom Immunoglobulin Production Capacity (2017-2028) & (K Vials)
Figure 13. Global Antivenom Immunoglobulin Production Capacity by Geographic Region: 2022 VS 2028
Figure 14. Antivenom Immunoglobulin Market Drivers
Figure 15. Antivenom Immunoglobulin Market Restraints
Figure 16. Antivenom Immunoglobulin Market Trends
Figure 17. Global Antivenom Immunoglobulin Sales Market Share by Manufacturer in 2021
Figure 18. Global Antivenom Immunoglobulin Revenue Market Share by Manufacturer in 2021
Figure 19. Antivenom Immunoglobulin Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 20. Top 3 Antivenom Immunoglobulin Manufacturer (Revenue) Market Share in 2021
Figure 21. Top 6 Antivenom Immunoglobulin Manufacturer (Revenue) Market Share in 2021
Figure 22. Global Antivenom Immunoglobulin Sales Market Share by Region (2017-2028)
Figure 23. Global Antivenom Immunoglobulin Revenue Market Share by Region (2017-2028)
Figure 24. North America Antivenom Immunoglobulin Revenue (2017-2028) & (USD Million)
Figure 25. Europe Antivenom Immunoglobulin Revenue (2017-2028) & (USD Million)
Figure 26. Asia-Pacific Antivenom Immunoglobulin Revenue (2017-2028) & (USD Million)
Figure 27. South America Antivenom Immunoglobulin Revenue (2017-2028) & (USD Million)
Figure 28. Middle East & Africa Antivenom Immunoglobulin Revenue (2017-2028) & (USD Million)
Figure 29. Global Antivenom Immunoglobulin Sales Market Share by Type (2017-2028)
Figure 30. Global Antivenom Immunoglobulin Revenue Market Share by Type (2017-2028)
Figure 31. Global Antivenom Immunoglobulin Price by Type (2017-2028) & (USD/Vial)
Figure 32. Global Antivenom Immunoglobulin Sales Market Share by Application (2017-2028)
Figure 33. Global Antivenom Immunoglobulin Revenue Market Share by Application (2017-2028)
Figure 34. Global Antivenom Immunoglobulin Price by Application (2017-2028) & (USD/Vial)
Figure 35. North America Antivenom Immunoglobulin Sales Market Share by Type (2017-2028)
Figure 36. North America Antivenom Immunoglobulin Sales Market Share by Application (2017-2028)
Figure 37. North America Antivenom Immunoglobulin Sales Market Share by Country (2017-2028)
Figure 38. North America Antivenom Immunoglobulin Revenue Market Share by Country (2017-2028)
Figure 39. United States Antivenom Immunoglobulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 40. Canada Antivenom Immunoglobulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Mexico Antivenom Immunoglobulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Europe Antivenom Immunoglobulin Sales Market Share by Type (2017-2028)
Figure 43. Europe Antivenom Immunoglobulin Sales Market Share by Application (2017-2028)
Figure 44. Europe Antivenom Immunoglobulin Sales Market Share by Country (2017-2028)
Figure 45. Europe Antivenom Immunoglobulin Revenue Market Share by Country (2017-2028)
Figure 46. Germany Antivenom Immunoglobulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Antivenom Immunoglobulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Antivenom Immunoglobulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Antivenom Immunoglobulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Antivenom Immunoglobulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Antivenom Immunoglobulin Sales Market Share by Region (2017-2028)
Figure 52. Asia-Pacific Antivenom Immunoglobulin Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Antivenom Immunoglobulin Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Antivenom Immunoglobulin Revenue Market Share by Region (2017-2028)
Figure 55. China Antivenom Immunoglobulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Antivenom Immunoglobulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Korea Antivenom Immunoglobulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Antivenom Immunoglobulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Antivenom Immunoglobulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Antivenom Immunoglobulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Antivenom Immunoglobulin Sales Market Share by Type (2017-2028)
Figure 62. South America Antivenom Immunoglobulin Sales Market Share by Application (2017-2028)
Figure 63. South America Antivenom Immunoglobulin Sales Market Share by Country (2017-2028)
Figure 64. South America Antivenom Immunoglobulin Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Antivenom Immunoglobulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Antivenom Immunoglobulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East & Africa Antivenom Immunoglobulin Sales Market Share by Type (2017-2028)
Figure 68. Middle East & Africa Antivenom Immunoglobulin Sales Market Share by Application (2017-2028)
Figure 69. Middle East & Africa Antivenom Immunoglobulin Sales Market Share by Region (2017-2028)
Figure 70. Middle East & Africa Antivenom Immunoglobulin Revenue Market Share by Region (2017-2028)
Figure 71. Turkey Antivenom Immunoglobulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Egypt Antivenom Immunoglobulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Antivenom Immunoglobulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Africa Antivenom Immunoglobulin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Antivenom Immunoglobulin in 2021
Figure 76. Manufacturing Process Analysis of Antivenom Immunoglobulin
Figure 77. Antivenom Immunoglobulin Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界のヒスタミン ヒト免疫グロブリン市場2022年：市場規模予測（～2028年）
  • 世界のウマ狂犬病免疫グロブリン（ERIG）市場2022年：市場規模予測（～2028年）
  • 分泌型免疫グロブリンA[SIgA]のグローバル市場展望 2023年-2029年：アレルギー疾患、感染症、消化管炎症、自己免疫疾患
  • 世界の血漿タンパク質製品市場2022年：市場規模予測（～2028年）
  • 原発性免疫不全治療薬のグローバル市場展望 2023年-2029年：免疫グロブリン補充療法、幹細胞/骨髄移植、抗生物質療法、遺伝子療法、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19156 )"世界の抗毒素免疫グロブリン市場2022年：市場規模予測（～2028年）" (英文：Global Antivenom Immunoglobulin Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。